What are the diagnostic tests available based on nccn
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Based on the patient's clinical summary, I'll outline the relevant diagnostic testing recommendations for Glioblastoma Multiforme (GBM) according to authoritative sources:
According to the NCCN Clinical Practice Guidelines for Central Nervous System Cancers, the standard diagnostic workup should include:
- Imaging Studies:
- MRI with and without contrast (which the patient has received, as evidenced by the documentation of enhancing lesions)
- Advanced imaging techniques such as: • MR Spectroscopy • Perfusion imaging • Diffusion imaging • PET imaging (the patient has already undergone C11-methionine PET imaging, as noted in the summary)
- Molecular Testing (NCCN Category 1 recommendation):
- IDH mutation status
- MGMT promoter methylation status
- 1p/19q codeletion testing
- ATRX mutation
- TERT promoter mutation
The National Cancer Institute (NCI) additionally recommends:
- Regular neurological examinations
- Cognitive function assessments
- Performance status evaluation (which is documented as 0 in this case)
Important note from the clinical summary:
- The document states "Molecular testing details not specified in available records" - this suggests a potential gap in documented testing that should be addressed according to current guidelines.
ASCO Guidelines also emphasize:
- The importance of regular surveillance imaging to monitor treatment response and disease progression
- The need for ongoing seizure assessment and management (particularly relevant given the patient's recent seizure history)
Recommendation based on guidelines: Since molecular testing details are not specified in the records, it would be important to verify whether comprehensive molecular testing has been performed according to current NCCN guidelines, as this could impact treatment decisions and clinical trial eligibility.
Always consult with healthcare providers for specific testing recommendations, as individual cases may require modified approaches based on clinical circumstances.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with diagnosis for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2